Nav: Home

Increase in biomarker linked with increased risk of heart disease, heart failure, death

June 08, 2016

In a study published online by JAMA Cardiology, Elizabeth Selvin, Ph.D., M.P.H., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues examined the association of 6-year change in high-sensitivity cardiac troponin T with incident coronary heart disease, heart failure and all-cause mortality.

High-sensitivity cardiac troponin T (hs-cTnT), a protein that can be measured via a blood test, is a biomarker of cardiovascular risk and could be approved in the United States for clinical use soon. Cardiac troponin is critical to the clinical diagnosis of heart attack, particularly among symptomatic persons with chest pain. However, little is known about the implications of changes in hs-cTnT levels over time. This analysis included 8,838 participants from the Atherosclerosis Risk in Communities Study who were initially free of coronary heart disease (CHD) and heart failure (HF) and who had hs-cTnT measured twice, 6 years apart.

Of the participants (average age, 56 years; 59 percent female; 21 percent black), there were 1,157 CHD events, 965 HF events, and 1,813 deaths overall. Incident detectable hs-cTnT (baseline, <0.005 ng/ml; follow-up, ? 0.005 ng/ml) was independently associated with subsequent CHD, HF and death relative to an hs-cTnT level less than 0.005 ng/ml at both visits. Individuals with the most marked hs-cTnT increases (e.g. baseline, < 0.005 ng/ml; follow-up, ? 0.014 ng/ml) had significantly increased risks for CHD, HF and death. In persons with decreasing hs-cTnT levels (e.g., 6-year reductions >50 percent from baseline), there was also evidence suggestive of lower risk for outcomes compared with persons with stable or increasing concentrations.

"Our results indicate that 2 measurements of hs-cTnT appear to be better than 1 for characterizing risk and that large increases in hs-cTnT are particularly deleterious. Temporal change in hs-cTnT may help guide the preventive management of asymptomatic persons at risk for CHD and adults with stage A or B HF," the authors write.
-end-
(JAMA Cardiology. Published online June 8, 2016; doi:10.1001/jamacardio.2016.0765. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Note: An accompanying commentary, "Biomarkers to Predict Risk in Apparently Well Populations," by James L. Januzzi Jr., M.D., of Massachusetts General Hospital, Boston, is available pre-embargo at the For The Media website.

Media Advisory: To contact co-author John W. McEvoy, M.B., B.Ch., M.H.S., call Vanessa McMains at 410-502-9410 or email vmcmain1@jhmi.edu.

The JAMA Network Journals

Related Heart Failure Articles:

New hope for treating heart failure
Heart failure patients who are getting by on existing drug therapies can look forward to a far more effective medicine in the next five years or so, thanks to University of Alberta researchers.
Activated T-cells drive post-heart attack heart failure
Chronic inflammation after a heart attack can promote heart failure and death.
ICU care for COPD, heart failure and heart attack may not be better
Does a stay in the intensive care unit give patients a better chance of surviving a chronic obstructive pulmonary disease (COPD) or heart failure flare-up or even a heart attack, compared with care in another type of hospital unit?
Tissue engineering advance reduces heart failure in model of heart attack
Researchers have grown heart tissue by seeding a mix of human cells onto a 1-micron-resolution scaffold made with a 3-D printer.
Smoking may lead to heart failure by thickening the heart wall
Smokers without obvious signs of heart disease were more likely than nonsmokers and former smokers to have thickened heart walls and reduced heart pumping ability.
After the heart attack: Injectable gels could prevent future heart failure (video)
During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells in the heart.
Heart failure after first heart attack may increase cancer risk
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a study today in the Journal of the American College of Cardiology.
Scientists use 'virtual heart' to model heart failure
A team of researchers have created a detailed computational model of the electrophysiology of congestive heart failure, a leading cause of death.
Increase in biomarker linked with increased risk of heart disease, heart failure, death
In a study published online by JAMA Cardiology, Elizabeth Selvin, Ph.D., M.P.H., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues examined the association of six-year change in high-sensitivity cardiac troponin T with incident coronary heart disease, heart failure and all-cause mortality.
1 in 4 patients develop heart failure within 4 years of first heart attack
One in four patients develop heart failure within four years of a first heart attack, according to a study in nearly 25,000 patients presented today at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure by Dr.

Related Heart Failure Reading:

Heart Failure Pocketcard Set
by M.D. Szady (Author), M.D. Bavry (Author)

Heart Failure Recovery: Complete Failure to Complete Recovery
by Ray Reynolds (Author)

Heart Failure Prevention & Treatment: A Companion book To All You Need To Know About cardiac Failure
by Alex Hall M.D (Author), Ifiokobong Ene (Contributor)

Heart Failure: A Companion to Braunwald's Heart Disease, 3e
by Douglas L. Mann MD (Author), G. Michael Felker MD MHS FACC FAHA (Author)

Living Well with Heart Failure, the Misnamed, Misunderstood Condition
by Edward K. Kasper (Author), Mary Knudson (Author)

Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management (HEART FAILURE: PATHOPHYSIOLOGY, MOLEC BIOL & CLIN MGT)
by Arnold M. Katz MD (Author), Marvin A. Konstam MD (Author)

Heart Failure: A Comprehensive Guide to Pathophysiology and Clinical Care
by Howard Eisen (Editor)

Heart Failure
by Richard Mabry (Author)

Heart Failure: An Incredibly Easy! Miniguide
by Springhouse (Editor)

MemoCharts Pharmacology: Drug Therapy for Congestive Heart Failure (Review chart)
by Howard Shen (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Why We Hate
From bullying to hate crimes, cruelty is all around us. So what makes us hate? And is it learned or innate? This hour, TED speakers explore the causes and consequences of hate — and how we can fight it. Guests include reformed white nationalist Christian Picciolini, CNN commentator Sally Kohn, podcast host Dylan Marron, and writer Anand Giridharadas.
Now Playing: Science for the People

#482 Body Builders
This week we explore how science and technology can help us walk when we've lost our legs, see when we've gone blind, explore unfriendly environments, and maybe even make our bodies better, stronger, and faster than ever before. We speak to Adam Piore, author of the book "The Body Builders: Inside the Science of the Engineered Human", about the increasingly amazing ways bioengineering is being used to reverse engineer, rebuild, and augment human beings. And we speak with Ken Thomas, spacesuit engineer and author of the book "The Journey to Moonwalking: The People That Enabled Footprints on the Moon" about...